Get the Stockscreener App
4.31
0.94%
0.04
After Hours:
4.29
-0.02
-0.46%
Acurx Pharmaceuticals Inc stock is traded at $4.31, with a volume of 13,012.
It is up +0.94% in the last 24 hours and down -2.82% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
See More
Previous Close:
$4.27
Open:
$4.19
24h Volume:
13,012
Relative Volume:
0.04
Market Cap:
$6.83M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-3.7478
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
+5.64%
1M Performance:
-2.82%
6M Performance:
-53.66%
1Y Performance:
-89.28%
1-Day Range:
$4.19
$4.34
1-Week Range:
$3.94
$4.34
52-Week Range:
$3.80
$44.00
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
4.31 | 6.45M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Is Acurx Pharmaceuticals Inc. trending in predictive chart models2025 Market Outlook & Verified Swing Trading Watchlist - Newser
Trend analysis for Acurx Pharmaceuticals Inc. this weekQuarterly Trade Report & Low Volatility Stock Recommendations - Newser
Has Acurx Pharmaceuticals Inc. found a price floorTrade Entry Summary & Daily Entry Point Alerts - Newser
Smart tools for monitoring Acurx Pharmaceuticals Inc.’s price actionWeekly Risk Report & Community Consensus Picks - Newser
Visual analytics tools that track Acurx Pharmaceuticals Inc. performanceWeekly Trend Summary & AI Powered Market Trend Analysis - Newser
Will Acurx Pharmaceuticals Inc. outperform the marketTrade Risk Assessment & AI Based Buy/Sell Signal Reports - Newser
What does recent volatility data suggest for Acurx Pharmaceuticals Inc.Share Buyback & Consistent Return Strategy Ideas - Newser
Real time social sentiment graph for Acurx Pharmaceuticals Inc.Portfolio Value Report & Free Accurate Trade Setup Notifications - Newser
Does Acurx Pharmaceuticals Inc. qualify in momentum factor screening2025 Momentum Check & Daily Stock Trend Reports - Newser
What to do if you’re stuck in Acurx Pharmaceuticals Inc.Trade Exit Report & Weekly High Conviction Trade Ideas - Newser
What data driven models say about Acurx Pharmaceuticals Inc.’s futureWeekly Risk Report & Daily Chart Pattern Signals - Newser
Will Acurx Pharmaceuticals Inc. rebound enough to break evenPortfolio Return Report & Low Drawdown Trading Techniques - Newser
How to integrate Acurx Pharmaceuticals Inc. into portfolio analysis tools2025 Price Momentum & Weekly High Return Forecasts - Newser
Short interest data insights for Acurx Pharmaceuticals Inc.Market Risk Analysis & Growth Focused Entry Reports - Newser
Why Acurx Pharmaceuticals Inc. stock attracts strong analyst attentionWeekly Earnings Recap & Low Risk High Reward Ideas - Newser
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events - Pensacola News Journal
Sentiment analysis tools applied to Acurx Pharmaceuticals Inc.2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - Newser
Analyzing recovery setups for Acurx Pharmaceuticals Inc. investorsEarnings Growth Report & Growth Focused Stock Pick Reports - Newser
Acurx Pharmaceuticals regains compliance with Nasdaq’s listing rules - MSN
Using R and stats models for Acurx Pharmaceuticals Inc. forecasting2025 Market Sentiment & Safe Entry Zone Tips - Newser
Is Acurx Pharmaceuticals Inc. stock poised for growth2025 Volume Leaders & Verified Entry Point Signals - Newser
Applying sector rotation models to Acurx Pharmaceuticals Inc.2025 Momentum Check & Consistent Profit Trading Strategies - Newser
Strategies to average down on Acurx Pharmaceuticals Inc.Quarterly Earnings Report & Weekly Market Pulse Updates - Newser
Acurx Pharmaceuticals Reports Reduced Losses Amid Ongoing R&D Efforts - MSN
What are the risks of holding Acurx Pharmaceuticals Inc.Weekly Trade Report & Safe Swing Trade Setup Alerts - Lancaster City Council
Published on: 2025-09-09 07:28:35 - Newser
What MACD signals say about Acurx Pharmaceuticals Inc.Swing Trade & Trade Opportunity Analysis - Newser
Can volume confirm reversal in Acurx Pharmaceuticals Inc.Market Growth Review & Capital Protection Trading Alerts - Newser
What technical models suggest about Acurx Pharmaceuticals Inc.’s comebackBear Alert & Community Consensus Picks - Newser
Acurx Pharmaceuticals Inc. Trading Near Value Zone — Recovery AheadJobs Report & Risk Controlled Stock Pick Alerts - beatles.ru
Using AI based signals to follow Acurx Pharmaceuticals Inc.Portfolio Return Summary & AI Driven Stock Reports - Newser
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):